Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

In December 2024, the American Gastroenterological Association (AGA) published an updated clinical guideline for the ...

Janus kinase (JAK) inhibitors are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis. Since ...

Acquisition of the constitutively active Janus kinase 2 (JAK2 ... and phosphotidylinositol 3-kinase (PI3K) signalling pathways, and transforms haematopoietic progenitors. The identification ...

a mutation in the Janus kinase 2 (JAK2) gene, which occurs in 50-60% of myelofibrosis cases. "The identification of that ...

Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis.

ATOPIC dermatitis (AD) is the most common chronic inflammatory skin condition, affecting up to 10% of adults and up to 20% of ...

Dizal (SSE: 688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and ...

ATI-2138 exhibits the ability to selectively and potently block interleukin-2-inducible T cell kinase (ITK) and Janus kinase 3 ... through the IL-2 receptor pathway, ATI-2138 brings a novel ...

Dizal announces new findings on golidocitinib; to present clinical results at ELCC 2025 in Paris on March 26-29: Shanghai Saturday, March 22, 2025, 17:00 Hrs [IST] Dizal, a biopha ...

Janus kinase inhibitors (JAKis ... Because these drugs specifically block cellular signalling pathways that are responsible for maintaining inflammatory responses, JAKi have been researched ...